Literature DB >> 23791072

The potential role of dopamine D₃ receptor neurotransmission in cognition.

Shinichiro Nakajima1, Philip Gerretsen, Hiroyoshi Takeuchi, Fernando Caravaggio, Tiffany Chow, Bernard Le Foll, Benoit Mulsant, Bruce Pollock, Ariel Graff-Guerrero.   

Abstract

Currently available treatments have limited pro-cognitive effects for neuropsychiatric disorders, such as schizophrenia, Parkinson's disease and Alzheimer's disease. The primary objective of this work is to review the literature on the role of dopamine D₃ receptors in cognition, and propose dopamine D₃ receptor antagonists as possible cognitive enhancers for neuropsychiatric disorders. A literature search was performed to identify animal and human studies on D₃ receptors and cognition using PubMed, MEDLINE and EMBASE. The search terms included "dopamine D₃ receptor" and "cognition". The literature search identified 164 articles. The results revealed: (1) D₃ receptors are associated with cognitive functioning in both healthy individuals and those with neuropsychiatric disorders; (2) D₃ receptor blockade appears to enhance while D₃ receptor agonism seems to impair cognitive function, including memory, attention, learning, processing speed, social recognition and executive function independent of age; and (3) D₃ receptor antagonists may exert their pro-cognitive effect by enhancing the release of acetylcholine in the prefrontal cortex, disinhibiting the activity of dopamine neurons projecting to the nucleus accumbens or prefrontal cortex, or activating CREB signaling in the hippocampus. These findings suggest that D₃ receptor blockade may enhance cognitive performance in healthy individuals and treat cognitive dysfunction in individuals with a neuropsychiatric disorder. Clinical trials are needed to confirm these effects.
Copyright © 2013 Elsevier B.V. and ECNP. All rights reserved.

Entities:  

Keywords:  Cognition; Dopamine D3 receptor; Dopamine D3 receptor antagonist

Mesh:

Substances:

Year:  2013        PMID: 23791072      PMCID: PMC3748034          DOI: 10.1016/j.euroneuro.2013.05.006

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  162 in total

1.  Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial.

Authors:  Douglas L Boggs; Deanna L Kelly; Robert P McMahon; James M Gold; David A Gorelick; Jared Linthicum; Robert R Conley; Fang Liu; James Waltz; Marilyn A Huestis; Robert W Buchanan
Journal:  Schizophr Res       Date:  2011-12-03       Impact factor: 4.939

2.  Mice lacking dopamine D2 and D3 receptors exhibit differential activation of prefrontal cortical neurons during tasks requiring attention.

Authors:  Sara B Glickstein; Deirdre A Desteno; Patrick R Hof; Claudia Schmauss
Journal:  Cereb Cortex       Date:  2004-11-10       Impact factor: 5.357

Review 3.  Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment.

Authors:  Per Svenningsson; Eric Westman; Clive Ballard; Dag Aarsland
Journal:  Lancet Neurol       Date:  2012-08       Impact factor: 44.182

4.  Influence of dopamine D3 receptor knockout on age-related decline of spatial memory.

Authors:  Bo Xing; Xia Meng; Shuguang Wei; Shengbin Li
Journal:  Neurosci Lett       Date:  2010-06-30       Impact factor: 3.046

5.  Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A.

Authors:  C Reavill; S G Taylor; M D Wood; T Ashmeade; N E Austin; K Y Avenell; I Boyfield; C L Branch; J Cilia; M C Coldwell; M S Hadley; A J Hunter; P Jeffrey; F Jewitt; C N Johnson; D N Jones; A D Medhurst; D N Middlemiss; D J Nash; G J Riley; C Routledge; G Stemp; K M Thewlis; B Trail; A K Vong; J J Hagan
Journal:  J Pharmacol Exp Ther       Date:  2000-09       Impact factor: 4.030

6.  Specific modulation of social memory in rats by cholinomimetic and nootropic drugs, by benzodiazepine inverse agonists, but not by psychostimulants.

Authors:  A Perio; J P Terranova; P Worms; R M Bluthe; R Dantzer; K Biziere
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 7.  The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders.

Authors:  P Sokoloff; J Diaz; B Le Foll; O Guillin; L Leriche; E Bezard; C Gross
Journal:  CNS Neurol Disord Drug Targets       Date:  2006-02       Impact factor: 4.388

Review 8.  Genetics of dopamine receptors and drug addiction: a comprehensive review.

Authors:  Bernard Le Foll; Alexandra Gallo; Yann Le Strat; Lin Lu; Philip Gorwood
Journal:  Behav Pharmacol       Date:  2009-02       Impact factor: 2.293

9.  A common variant in DRD3 receptor is associated with autism spectrum disorder.

Authors:  Mariken de Krom; Wouter G Staal; Roel A Ophoff; Judith Hendriks; Jan Buitelaar; Barbara Franke; Maretha V de Jonge; Patrick Bolton; David Collier; Sarah Curran; Herman van Engeland; Jan M van Ree
Journal:  Biol Psychiatry       Date:  2008-12-05       Impact factor: 13.382

10.  A randomized exploratory trial of an α-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia.

Authors:  Jeffrey A Lieberman; Geoffrey Dunbar; Anthony C Segreti; Ragy R Girgis; Frances Seoane; Jessica S Beaver; Naihua Duan; David A Hosford
Journal:  Neuropsychopharmacology       Date:  2012-12-18       Impact factor: 7.853

View more
  58 in total

1.  Exploring the relationship between social attachment and dopamine D2/3 receptor availability in the brains of healthy humans using [11C]-(+)-PHNO.

Authors:  Fernando Caravaggio; Jun Ku Chung; Philip Gerretsen; Gagan Fervaha; Shinichiro Nakajima; Eric Plitman; Yusuke Iwata; Alan Wilson; Ariel Graff-Guerrero
Journal:  Soc Neurosci       Date:  2016-02-29       Impact factor: 2.083

Review 2.  Dopamine D3 receptor: A neglected participant in Parkinson Disease pathogenesis and treatment?

Authors:  Pengfei Yang; Joel S Perlmutter; Tammie L S Benzinger; John C Morris; Jinbin Xu
Journal:  Ageing Res Rev       Date:  2019-11-22       Impact factor: 10.895

3.  Expression of dopamine D2 and D3 receptors in the human retina revealed by positron emission tomography and targeted mass spectrometry.

Authors:  Fernando Caravaggio; Enzo Scifo; Etienne L Sibille; Sergio E Hernandez-Da Mota; Philip Gerretsen; Gary Remington; Ariel Graff-Guerrero
Journal:  Exp Eye Res       Date:  2018-06-05       Impact factor: 3.467

4.  Acute and long-term effects of adolescent methylphenidate on decision-making and dopamine receptor mRNA expression in the orbitofrontal cortex.

Authors:  Leslie R Amodeo; Eliza Jacobs-Brichford; Matthew S McMurray; Jamie D Roitman
Journal:  Behav Brain Res       Date:  2017-02-14       Impact factor: 3.332

5.  Dopamine effects on frontal cortical blood flow and motor inhibition in Parkinson's disease.

Authors:  Paula Trujillo; Nelleke C van Wouwe; Ya-Chen Lin; Adam J Stark; Kalen J Petersen; Hakmook Kang; David H Zald; Manus J Donahue; Daniel O Claassen
Journal:  Cortex       Date:  2019-01-29       Impact factor: 4.027

6.  Dopaminergic gene methylation is associated with cognitive performance in a childhood monozygotic twin study.

Authors:  Candace R Lewis; Adrienne Henderson-Smith; Reagan S Breitenstein; Hayley A Sowards; Ignazio S Piras; Matthew J Huentelman; Leah D Doane; Kathryn Lemery-Chalfant
Journal:  Epigenetics       Date:  2019-03-16       Impact factor: 4.528

7.  Randomized, double-blind, placebo-controlled study of F17464, a preferential D3 antagonist, in the treatment of acute exacerbation of schizophrenia.

Authors:  Istvan Bitter; Jeffrey A Lieberman; Florence Gaudoux; Pierre Sokoloff; Mélanie Groc; Rajeev Chavda; Cécile Delsol; Laurence Barthe; Valérie Brunner; Carine Fabre; Marine Fagard; Agnès Montagne; Françoise Tonner
Journal:  Neuropsychopharmacology       Date:  2019-03-01       Impact factor: 7.853

8.  D3 Receptors Regulate Excitability in a Unique Class of Prefrontal Pyramidal Cells.

Authors:  Rebecca L Clarkson; Alayna T Liptak; Steven M Gee; Vikaas S Sohal; Kevin J Bender
Journal:  J Neurosci       Date:  2017-05-18       Impact factor: 6.167

9.  Selective activation of Dopamine D3 receptors and norepinephrine transporter blockade enhances sustained attention.

Authors:  Courtney A Marshall; Zachary D Brodnik; Ole V Mortensen; Maarten E A Reith; Jed S Shumsky; Barry D Waterhouse; Rodrigo A España; Sandhya Kortagere
Journal:  Neuropharmacology       Date:  2019-01-08       Impact factor: 5.250

10.  Dopamine D3 receptors in the basolateral amygdala and the lateral habenula modulate cue-induced reinstatement of nicotine seeking.

Authors:  Maram A T M Khaled; Abhiram Pushparaj; Patricia Di Ciano; Jorge Diaz; Bernard Le Foll
Journal:  Neuropsychopharmacology       Date:  2014-07-07       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.